foxo4-dri senolytic peptide study 2017 cell Frontiers CHK2-USP37 axis stabilizes FOXO4 to
CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS Full article: Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics Buy FOXO4 DRI (Proxofim) Senolytic Peptide For Cellular Renewal The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data
Pay in 4 interest-free payments of $5.71 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




